ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
FGFR Inhibitor AZD4547 Disrupts Inflammatory CAF Crosstalk With Cancer Cells and Macrophages and Attenuates Metastasis in Pancreatic Cancer.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer-associated fibroblasts (CAFs) are key cell types within the tumor microenvironment (TME), responsible for their pro-tumorigenic effects and metastasis. Specifically, inflammatory CAFs (iCAFs), a CAF subtype, are known to induce tumor cell progression, migration, and immunosuppression. Fibroblast growth factor receptors (FGFRs) play a crucial role in cell differentiation, migration, and proliferation. In this study, we investigated the effect of FGFR kinase inhibitor AZD4547 (AZD), a clinical-stage drug, on iCAF differentiation and iCAF-mediated effects on the tumor-stroma interaction in vitro and in vivo. Treatment with AZD inhibited the differentiation of human pancreatic stellate cells into iCAFs using IL-1α, as shown with reduced IL-6 expression. FGFR1, 2, 3, and 4 were upregulated in iCAFs, which were inhibited by AZD. Treatment with AZD also attenuated the iCAF-mediated paracrine effect on the PDAC cell-induced migration and epithelial-mesenchymal transition of tumor cells, as well as polarization of macrophages towards the M1 phenotype in vitro. Furthermore, AZD significantly reduced the growth of tumor cells and fibroblasts in co-cultured 3D heterospheroids in vitro. In vivo, treatment with AZD attenuated the tumor growth in the syngeneic subcutaneous KPC murine tumor model. Interestingly, flow cytometry and immunofluorescent staining analyses on isolated tumors revealed that AZD-treated tumors had a reduced iCAF population and M2-type macrophages. Furthermore, we found that AZD treatment reduced the liver metastasis, as shown with the reduction of ki-67 and p53 tumor markers in the AZD-treated group compared to the vehicle group. Altogether, this study demonstrates that FGFRs are overexpressed on iCAFs and their inhibition using AZD diminishes iCAF-mediated paracrine signaling with tumor cells and macrophages, thereby attenuating tumor growth and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.